Physician profile
Nirav Mistry
NPI 1912162066
$3,562.86
in general payments reported to CMS, 2019-2025
32 companies · $223 in 2025
The $223 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $391 · 2021: $948 · 2022: $902 · 2023: $355 · 2024: $563 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,141.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $448.96 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $361.30 | 2020-2024 | Andexxa, Tezspire, Fasenra |
| La Jolla Pharmaceutical Company | $342.34 | 2021-2023 | Giapreza |
| Abbvie INC. | $278.17 | 2021-2025 | |
| Gilead Sciences, INC. | $251.24 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $227.56 | 2021-2023 | Ultomiris |
| Csl Behring | $176.67 | 2019-2023 | Kcentra |
| Edwards Lifesciences Corporation | $162.22 | 2021 | |
| Glaxosmithkline, LLC. | $151.75 | 2024-2025 | Nucala, Trelegy Ellipta |
| Ceribell, INC. | $139.16 | 2024 | Pocket Eeg Device |
| Haemonetics Corporation | $121.21 | 2024 | Teg6s Hemostasis System |
| Genzyme Corporation | $120.33 | 2024-2025 | |
| Chiesi USA, INC. | $96.45 | 2022-2024 | Cleviprex, Kengreal |
| Allergan, INC. | $88.66 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $60.98 | 2024 | Opsumit, Uptravi |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $55.39 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $53.49 | 2019-2023 | Zerbaxa, Recarbrio |
| Mylan Specialty L.P. | $52.70 | 2021-2024 | Yupelri |
| United Therapeutics Corporation | $51.95 | 2024-2025 | Tyvaso, Tyvaso |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.09 | 2021-2022 | |
| Mindray Ds USA, INC. | $43.87 | 2022 | |
| Boston Scientific Corporation | $36.64 | 2022 | |
| Janssen Pharmaceuticals, INC | $34.60 | 2020-2023 | Xarelto |
| Mallinckrodt Hospital Products INC. | $27.09 | 2020 | |
| Pulmonx Corporation | $26.29 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Melinta Therapeutics, LLC | $26.23 | 2022-2023 | Vabomere, Kimyrsa, Rezzayo |
| Medline Industries LP | $15.11 | 2023 | |
| Ucb, INC. | $15.00 | 2020 | |
| Philips North America LLC | $14.63 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.88 | 2025 | Ofev |
| Shionogi INC | $13.18 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirav Mistry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.